N,N'-Bis[(2-oxo-1,3-oxazolidin-3-yl)]phosphorodiamidic chloride | 102054-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: N,N'-Bis[(2-oxo-1,3-oxazolidin-3-yl)]phosphorodiamidic chloride
• 英文别名: 3-[[chloro-[(2-oxo-1,3-oxazolidin-3-yl)amino]phosphoryl]amino]-1,3-oxazolidin-2-one
• CAS: 102054-53-5
• 化学式: C₆H₁₀ClN₄O₅P
• 分子量: 284.59
• InChiKey: IZLCBIAXXCKIIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Dane salt 、 (E)-N-(4-methoxybenzylidene)4-methylaniline 、 N,N'-Bis[(2-oxo-1,3-oxazolidin-3-yl)]phosphorodiamidic chloride 以10%的产率得到
  参考文献：
  名称：

  AIZPURUA, J. M.;GANBOA, I.;COSSIO, F. P.;GONZALEZ, A.;ARRIETA, A.;PALOMO,+, TETRAHEDRON LETT., 1984, 25, N 35, 3905-3908

  摘要：

  DOI：

文献信息

• Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
  申请人：Wyeth Holdings Corporation

  公开号：US20040063904A1

  公开（公告）日：2004-04-01

  The invention is a process for the preparation of compounds of the Formula I: 1 where R 1 , R 2 , R 3 , R 4 and R 5 are defined in the specification, which are intermediates useful for the preparation of tubulin inhibitors which are useful in the treatment of cancer.

  这项发明是一种用于制备式I化合物的方法： 1 其中R 1 ，R 2 ，R 3 ，R 4 和R 5 在规范中有定义，这些中间体对于制备对抗癌症治疗中有用的微管蛋白抑制剂是有用的。
• Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
  申请人：American Cyanamid Company

  公开号：US20030130238A1

  公开（公告）日：2003-07-10

  Compounds of the formula 1 are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease and HIV.

  式1的化合物在治疗由TNF-α介导的疾病条件中很有用，如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病、退行性软骨丧失、移植排斥、虚弱、炎症、发热、胰岛素抵抗、脓毒性休克、充血性心力衰竭、中枢神经系统炎症性疾病、炎症性肠病和艾滋病。
• Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
  申请人：Wyeth Holdings Corporation

  公开号：US20040127524A1

  公开（公告）日：2004-07-01

  Hydroxamic acids having the formula 1 are useful in treating disease conditions mediated by TNF-□, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.

  具有公式1的羟甲酸在治疗由TNF-α介导的疾病情况中具有用处，例如类风湿性关节炎、移植排斥、虚弱、炎症、发热、胰岛素抵抗、脓毒性休克、充血性心力衰竭、中枢神经系统的炎症性疾病、炎症性肠病或HIV感染。
• Process for synthesizing beta-lactamase inhibitor intermediates
  申请人：Wyeth Holdings Corporation

  公开号：US20040242874A1

  公开（公告）日：2004-12-02

  There is provided a process for the preparation of bicyclicheteroaryl carboxaldehydes having the structural Formula I where X and Y are defined in the specification 1 The bicyclic heteroaryl carboxaldehydes are useful as intermediates in the preparation of &bgr;-lactamase inhibitors.

  提供了一种制备具有结构式I的双环杂环芳基羰基的方法，其中X和Y在规范中定义。这些双环杂环芳基羰基在β-内酰胺酶抑制剂的制备中作为中间体是有用的。
• SYNTHETIC METHODS PERTAINING TO TERT-BUTYL-BENZENE-BASED COMPOUNDS
  申请人：Boston Scientific Scimed, Inc.

  公开号：US20130190525A1

  公开（公告）日：2013-07-25

  According to some aspects, the present disclosure pertains to methods of forming dimethyl 5-tert-butylisophthalate which comprise comprising converting 5-tert-butylisophthalic acid into dimethyl 5-tert-butylisophthalate in synthesis procedures that comprises methanol and a dehydrating agent as chemical reagents. In other aspects, the present disclosure pertains to methods of forming 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene that comprise deprotonating 5-tert-butyl-1,3-bis(1-hydroxy-1-methylethyl)benzene with a Brønsted-Lowry superbase and methylating the deprotonated 5-tert-butyl-1,3-bis(1-hydroxy-1-methylethyl)benzene to form the 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene.

  根据某些方面，本公开涉及形成二甲基5-叔丁基异苯二甲酸酯的方法，包括将5-叔丁基异苯二甲酸转化为二甲基5-叔丁基异苯二甲酸酯，在合成过程中使用甲醇和脱水剂作为化学试剂。在其他方面，本公开涉及形成5-叔丁基-1,3-双(1-甲氧基-1-甲基乙基)苯的方法，包括用布朗斯特-洛瑞超碱去质子化5-叔丁基-1,3-双(1-羟基-1-甲基乙基)苯，并甲基化去质子化的5-叔丁基-1,3-双(1-羟基-1-甲基乙基)苯以形成5-叔丁基-1,3-双(1-甲氧基-1-甲基乙基)苯。